{
  "meta": {
    "title": "Steroids_And_Calcium_Metabolism",
    "url": "https://brainandscalpel.vercel.app/steroids-and-calcium-metabolism-e48da5ce.html",
    "scrapedAt": "2025-11-30T11:19:54.160Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">PTU</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Steroids</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Diuretics</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 34-year-old woman comes for a follow-up visit 2 months after RAIA. She reports improved symptoms but new-onset double vision. Examination shows conjunctival injection, proptosis, and lid lag. Slit-lamp examination reveals mild corneal ulcerations. The patient is given an additional medication that improves her diplopia and proptosis. What drug is that?</span></p>",
      "unique_key": "DT1166351",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166351,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Glucocorticoids are the treatment of choice for moderate-to-severe Graves ophthalmopathy</strong>, particularly when it is triggered or worsened by radioactive iodine ablation (RAIA).</p>\r\n<ul>\r\n<li><strong>RAIA is associated with the development or exacerbation of Graves ophthalmopathy</strong> due to increased levels of anti-TSH receptor antibodies post-treatment.</li>\r\n<li>These antibodies stimulate:\r\n<ul>\r\n<li>Orbital fibroblasts &rarr; &uarr; Glycosaminoglycan (GAG) synthesis</li>\r\n<li>Orbital adipocytes &rarr; &uarr; Proliferation</li>\r\n</ul>\r\n</li>\r\n<li>GAGs are <strong>hyperosmolar</strong>, drawing fluid into the interstitial space and causing <strong>oedema</strong>.</li>\r\n<li><strong>Increased GAGs + oedema + adipocyte proliferation</strong> &rarr; &uarr; Orbital pressure &rarr; <strong>Exophthalmos, ophthalmoplegia, diplopia, corneal ulceration</strong>.</li>\r\n<li><strong>Glucocorticoids (e.g., prednisolone)</strong> reduce orbital inflammation and symptoms through:\r\n<ul>\r\n<li>Anti-inflammatory and immunosuppressive action</li>\r\n<li>Inhibition of GAG production</li>\r\n<li>&darr; Orbital oedema and pressure</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001344d4e08-3f9f-40c2-a4c8-69886288e1db.png\">\r\n<p><strong>(Other options ruled out)</strong></p>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Prednisone</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">OCP</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Omeprazole</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old woman has been on L-thyroxine therapy for 2 years with adequate therapeutic response. However, with all of the following drugs, the dose of L-thyroxine is to be increased except:</span></p>",
      "unique_key": "DT1166373",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166373,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Certain drugs and conditions can either increase or decrease the requirement for L-thyroxine therapy by affecting its <strong>absorption, metabolism, or protein binding</strong>. Glucocorticoids like prednisone <strong>decrease serum TBG</strong> levels and may <strong>reduce</strong> the need for thyroxine supplementation, making them the <strong>exception</strong> in this list.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510016476cd30-1dfe-4f11-bc98-5dbaf506a492.png\">\r\n<p><strong>(Other options ruled out)</strong></p>\r\n<ul>\r\n<li>Estrogens and SERMs <strong>increase</strong> TBG levels &rarr; more T4 is protein-bound &rarr; less free T4 &rarr; dose needs to be <strong>increased</strong>.</li>\r\n<li>Omeprazole <strong>decreases absorption</strong> by reducing gastric acidity.</li>\r\n<li>Enzyme inducers like <strong>phenytoin, carbamazepine</strong> accelerate <strong>hepatic metabolism</strong> of thyroid hormones.</li>\r\n<li>Propranolol <strong>blocks peripheral conversion</strong> of T4 to T3, possibly reducing effectiveness.</li>\r\n<li><strong>Glucocorticoids</strong> like prednisone reduce TBG levels, thus <strong>increasing free T4</strong> availability &rarr; dose of L-thyroxine may be <strong>lowered</strong>.</li>\r\n</ul>",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibition of nuclear factor-KB</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Formation of DNA strand breaks</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Stimulation of osteoblast activity</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Apoptosis of osteoclasts</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 63-year-old man presents with headaches and back pain since 6 months. Examination shows mild sensorineural hearing loss. Serum concentration of alkaline phosphatase is increased. An X-ray of the skull is shown. The most appropriate pharmacotherapy for this patient is a drug that has which of the following mechanisms of action?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510016e0d52d4-a447-4244-9c9a-ece4dc299b9d.png\"></span></p>",
      "unique_key": "DT1166379",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166379,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The combination of <strong>hearing loss, headaches, and an elevated alkaline phosphatase concentration</strong> is concerning for a diagnosis of <strong>Paget's disease</strong> of bone.</p>\r\n<ul>\r\n<li>The x-ray showing characteristic deformities of bone, including <strong>thickening of the calvaria, sclerotic and osteolytic lesions, and osteoblastic lesions</strong>, confirms the diagnosis.</li>\r\n<li>The mainstay of<strong> treatment</strong> for Paget's disease of bone is <strong>bisphosphonate therapy</strong>, which functions by inducing apoptosis of osteoclasts. These drugs bind directly to the bone surface and are eventually taken up by osteoclasts during bone resorption. Once within a cell, they interfere with osteoclast survival, leading to apoptosis and reduced bone resorption.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510011e334d4b-2c08-4446-ae63-cdc01f2212f1.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Inhibition of nuclear factor-KB (Option A):</strong> This is the mechanism of <strong>denosumab</strong>, a monoclonal antibody against RANKL. It is used for osteoporosis and malignancy-related bone loss, <strong>not first-line</strong> for Paget's disease.</p>\r\n<p><strong>Formation of DNA strand breaks (Option B):</strong> This is characteristic of <strong>alkylating agents or chemotherapeutic drugs</strong> like bleomycin or cyclophosphamide. These are <strong>not used</strong> in Paget's disease.</p>\r\n<p><strong>Stimulation of osteoblast activity (Option C):</strong> Drugs like <strong>teriparatide</strong> stimulate osteoblasts but are <strong>contraindicated in Paget's disease</strong> due to the risk of osteosarcoma and high bone turnover states.</p>",
      "correct_choice_id": 24,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Etidronate</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Risedronate</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Raloxifene</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Teriparatide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following inhibits the enzyme farnesyl pyrophosphate synthase, disrupting osteoclast metabolism and promoting osteoclast apoptosis?</span></p>",
      "unique_key": "DT1166384",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166384,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Risedronate is a third-generation nitrogen-containing bisphosphonate that acts by inhibiting <strong>farnesyl pyrophosphate synthase</strong>, a key enzyme in the mevalonate pathway. This inhibition impairs osteoclast function and promotes apoptosis, thereby reducing bone resorption.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251003a81c0f04-36cf-4331-9bcb-461e164790d3.png\">\r\n<p><strong>(Other options ruled out)</strong></p>\r\n",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Antibiotic prophylaxis</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium supplementation</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Smoking/tobacco cessation</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral rinsing</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 75-year-old woman presented with progressive pain and swelling of her right jaw over the past 8 weeks. She was diagnosed with osteoporosis 12 months ago, on oral alendronate to be taken weekly. Intraoral examination shows gingival erythema and swelling around the right lower molars without purulent discharge. A part of the alveolar bone of the mandible in the same area is exposed. Which of the following is most likely to have prevented this patient's orofacial disease?</span></p>",
      "unique_key": "DT1166388",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166388,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The patient presents with signs suggestive of <strong>medication-related osteonecrosis of the jaw (MRONJ)</strong>, a complication seen with long-term <strong>bisphosphonate</strong> use, such as <strong>alendronate</strong>.</p>\r\n<ul>\r\n<li><strong>Key risk factor:</strong> Invasive dental procedures in patients on antiresorptive therapy (e.g., bisphosphonates or RANKL inhibitors).</li>\r\n<li><strong>Prevention strategies include:</strong>\r\n<ul>\r\n<li><strong>A comprehensive dental evaluation</strong> prior to starting therapy to address dental infections or unrestorable teeth.</li>\r\n<li><strong>Daily oral care</strong>: Proper oral hygiene measures such as <strong>oral rinsing</strong>, brushing, flossing, and routine dental visits are strongly advised after therapy initiation.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Management is conservative</strong>: Antibiotics, improved oral hygiene, and minimal debridement; <strong>surgery is avoided</strong> unless necessary.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Antibiotic prophylaxis (Option A):</strong> May be used before dental procedures, but does <strong>not prevent</strong> chronic MRONJ if hygiene is neglected. It plays a supportive role, not a preventive one.</p>\r\n<p><strong>Calcium supplementation (Option B):</strong> Used to enhance bone mineral density in osteoporosis, but has <strong>no role</strong> in preventing osteonecrosis of the jaw.</p>\r\n<p><strong>Smoking/tobacco cessation (Option C):</strong> While smoking is a general risk factor for poor wound healing, it is <strong>not the primary preventive measure</strong> for bisphosphonate-associated jaw necrosis.</p>",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Raloxifene</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Teriparatide</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Denosumab</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcitonin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs acts by mimicking osteoprotegerin?</span></p>",
      "unique_key": "DT1166390",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166390,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Denosumab</strong> acts by binding to <strong>RANK ligand (RANKL)</strong>, mimicking the natural action of <strong>osteoprotegerin</strong>. This inhibits osteoclast differentiation, activation, and survival, thereby reducing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.</p>\r\n<ul>\r\n<li>It is a fully human monoclonal antibody with high affinity for RANKL.</li>\r\n<li>It effectively inhibits the interaction of RANKL with its receptor RANK on osteoclasts and osteoclast precursors.</li>\r\n<li>Particularly indicated in patients at high risk of fracture and in those intolerant or unresponsive to bisphosphonates.</li>\r\n<li>Denosumab is administered subcutaneously every 6 months.</li>\r\n</ul>\r\n<p><strong>Note:</strong> Because it mimics osteoprotegerin - a decoy receptor for RANKL - it prevents RANKL from activating RANK, which would otherwise promote osteoclast formation and bone resorption.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Raloxifene (Option A):</strong> A selective estrogen receptor modulator (SERM); it reduces bone resorption by estrogenic agonism on bone, not by inhibiting RANKL.</p>\r\n<p><strong>Teriparatide (Option B):</strong> Recombinant PTH (1-34); increases bone formation by stimulating osteoblast activity; does not interact with RANKL or mimic osteoprotegerin.</p>\r\n<p><strong>Calcitonin (Option D):</strong> A Hormone that directly inhibits osteoclast activity and decreases bone resorption but does not mimic osteoprotegerin or inhibit RANKL.</p>",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Decrease the absorption of calcium from bone</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase PTH formation</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase renal production of erythropoietin</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase the absorption of calcium from the gastrointestinal tract</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The active metabolites of vitamin D act through a nuclear receptor to produce which of the following effects?</span></p>",
      "unique_key": "DT1166392",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166392,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The active metabolites of vitamin D - particularly 1,25-dihydroxyvitamin D (calcitriol) - bind to nuclear vitamin D receptors and regulate transcription of genes involved in calcium and phosphate homeostasis.</p>\r\n<p>They <strong>increase serum calcium and phosphate</strong> by:</p>\r\n<ul>\r\n<li>Promoting <strong>intestinal absorption</strong> of calcium and phosphate</li>\r\n<li>Enhancing <strong>bone resorption</strong></li>\r\n<li>Reducing <strong>renal excretion</strong> of calcium and phosphate</li>\r\n<li>Inhibiting <strong>parathyroid hormone (PTH)</strong> formation through feedback suppression</li>\r\n</ul>\r\n<p>These effects collectively help in maintaining mineral ion homeostasis and bone turnover.</p>\r\n<p>Thus, they help increase serum calcium and phosphate levels and maintain mineral ion homeostasis.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251003cb089dbe-41bf-4085-8463-8677799b7646.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Decrease the absorption of calcium from bone (Option A):</strong> Incorrect; active vitamin D enhances bone resorption along with PTH to raise calcium levels.</p>\r\n<p><strong>Increase PTH formation (Option B):</strong> Incorrect; active vitamin D inhibits PTH production via negative feedback.</p>\r\n<p><strong>Increase renal production of erythropoietin (Option C):</strong> Incorrect; erythropoietin synthesis is primarily regulated by hypoxia, not vitamin D.</p>",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Advise to drink large quantities of water with the tablets and remain in an upright position for at least 30 minutes.</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Advise to eat fatty food with tablets and remain in an upright position for at least 30 minutes.</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Start calcium and vitamin D</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">It should be started before treatment with teriparatide.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old postmenopausal woman with osteoporosis began oral therapy with alendronate. What would you not advise?</span></p>",
      "unique_key": "DT1166393",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166393,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Alendronate is an oral bisphosphonate that can cause significant <strong>oesophageal irritation</strong>, ulcers, and even strictures if not taken properly. It should <strong>never be taken with food</strong>, especially <strong>fatty food</strong>, because it <strong>markedly reduces absorption</strong>. Instead:</p>\r\n<ul>\r\n<li>It should be taken <strong>on an empty stomach with a full glass of water</strong>, and the patient should <strong>remain upright for at least 30 minutes</strong> to minimise oesophageal adverse effects.</li>\r\n<li>Patients should <strong>avoid any food, calcium supplements, or other medications</strong> for at least 30-60 minutes after ingestion to ensure proper absorption.</li>\r\n<li><strong>Supplemental calcium and vitamin D</strong> are necessary to correct or prevent deficiencies and improve therapeutic outcomes.</li>\r\n<li>Alendronate <strong>should be given prior to starting teriparatide</strong> if using sequential therapy, since bisphosphonates reduce bone resorption and preserve bone mass, and teriparatide stimulates bone formation.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001358184dd-efe0-4a68-bfd4-ce2f9af6c0ed.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Advise to drink large quantities of water with the tablets and remain in an upright position for at least 30 min (Option A)</strong>: Prevents oesophagal irritation, ensures the tablet passes rapidly into the stomach.</p>\r\n<p><strong>Start calcium and vitamin D (Option C): </strong>Necessary to prevent hypocalcemia and optimise therapeutic response to bisphosphonates.</p>\r\n<p><strong>It should be started before treatment with teriparatide (Option D):</strong> Sequential use starting with bisphosphonates and followed by teriparatide is standard in patients with high fracture risk</p>",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Acts by increased bone growth</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Administered in continuous fashion</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased risk of osteosarcoma</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Contraindicated in patient with prior radiation therapy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not true about Teriparatide ?</span></p>",
      "unique_key": "DT1166394",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166394,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Teriparatide is administered in a pulsatile (intermittent) manner</strong> to selectively stimulate osteoblasts and promote bone formation. Continuous administration would instead favour bone resorption due to increased osteoclast activity.</p>\r\n<ul>\r\n<li><strong>Mechanism of Action:</strong>\r\n<ul>\r\n<li>Teriparatide is a recombinant human PTH(1-34).</li>\r\n<li>Stimulates osteoblastic bone formation when given intermittently.</li>\r\n<li>Enhances bone mineral density (BMD), especially at vertebral and femoral sites.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Therapeutic Uses:</strong>\r\n<ul>\r\n<li>Indicated in osteoporosis with high fracture risk.</li>\r\n<li>Also used in men and postmenopausal women at high risk of vertebral or nonvertebral fractures.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Adverse Effects and Contraindications:</strong>\r\n<ul>\r\n<li><strong>Increased risk of osteosarcoma</strong> observed in animal studies.</li>\r\n<li>Contraindicated in patients with:\r\n<ul>\r\n<li><strong>Prior skeletal radiation therapy</strong></li>\r\n<li><strong>Paget disease</strong></li>\r\n<li><strong>Unexplained elevated alkaline phosphatase</strong></li>\r\n<li><strong>Bone metastasis or skeletal malignancies</strong></li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Acts by increased bone growth (Option A):</strong> Teriparatide stimulates new bone formation via osteoblast activation.</p>\r\n<p><strong>Increased risk of osteosarcoma (Option C):</strong> Seen in preclinical (rat) studies with long-term use.</p>\r\n<p><strong>Contraindicated in patients with prior radiation therapy (Option D):</strong> Due to increased osteosarcoma risk in previously irradiated bone.</p>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydrochlorothiazide </span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Pamidronate</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Raloxifene</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Teriparatide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs is most useful for the treatment of hypercalcemia in Paget's disease?</span></p>",
      "unique_key": "DT1166396",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166396,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Pamidronate</strong> is a bisphosphonate that <strong>inhibits osteoclast-mediated bone resorption</strong>. It is used parenterally to<strong> manage hypercalcemia in Paget's disease</strong>, as well as in <strong>malignancy-associated hypercalcemia</strong>. It is 100-1000 times more potent than etidronate and is one of the preferred agents for treating increased skeletal remodelling and calcium release.</p>\r\n<ul>\r\n<li>Paget's disease involves increased bone resorption and disorganised bone formation, often accompanied by hypercalcemia.</li>\r\n<li>Pamidronate acts by binding to hydroxyapatite in bone and inhibiting osteoclast activity, thereby reducing calcium release.</li>\r\n<li>It is preferred in patients requiring rapid reduction of serum calcium, especially when oral bisphosphonates are less feasible.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001930b3719-dbef-4ea6-80f0-2cb797e9843b.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Hydrochlorothiazide (Option A):</strong> A thiazide diuretic; it reduces urinary calcium excretion and is contraindicated in hypercalcemia. It is not used in Paget's disease.</p>\r\n<p><strong>Raloxifene (Option C):</strong> A selective estrogen receptor modulator (SERM); used for osteoporosis prevention and treatment. It has no role in the acute management of hypercalcemia or Paget's disease.</p>\r\n<p><strong>Teriparatide (Option D):</strong> Recombinant human PTH analogue that stimulates bone formation. It may worsen hypercalcemia and is contraindicated in Paget's disease.</p>",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcitonin nasal spray</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Tamoxifene</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Risedronate</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Transdermal estradiol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old woman with a history of osteoporosis comes for a Colles' fracture after a recent fall. Which of the following drugs is most appropriate for this patient?</span></p>",
      "unique_key": "DT1166397",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166397,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Risedronate is a third-generation bisphosphonate and the drug of choice for the treatment and prevention of postmenopausal osteoporosis, including in patients with a fragility fracture (like a Colles' fracture). It inhibits osteoclast-mediated bone resorption, thereby improving bone mineral density and reducing the risk of future fractures.</p>\r\n<ul>\r\n<li>Bisphosphonates like <strong>risedronate, alendronate, and ibandronate</strong> are considered first-line therapies for osteoporosis.</li>\r\n<li>Risedronate is well-absorbed, localises to bone, and is retained in the matrix where it inhibits osteoclastic activity.</li>\r\n<li>It is effective in reducing vertebral and nonvertebral fractures.</li>\r\n<li>Use is contraindicated in patients with oesophageal abnormalities or difficulty swallowing.</li>\r\n</ul>\r\n<p>For optimal efficacy, risedronate must be taken with a full glass of water at least 30 minutes before the first food or drink of the day.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510014c85c798-b072-4120-a6d9-3697c1bd0b22.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Calcitonin nasal spray (Option A):</strong> A less effective alternative for osteoporosis; mostly used for short-term pain relief in vertebral compression fractures and Paget's disease. Not preferred for long-term osteoporosis management.</p>\r\n<p><strong>Tamoxifene (Option B):</strong> A selective estrogen receptor modulator (SERM) used in estrogen receptor-positive breast cancer prevention and treatment. Though it has partial agonist effects on bone, raloxifene is the preferred SERM for osteoporosis, not tamoxifene.</p>\r\n<p><strong>Transdermal estradiol (Option D):</strong> Estrogen replacement can improve BMD but is not a first-line treatment due to risks of thromboembolism, breast cancer, and cardiovascular disease. Used only when other agents are contraindicated and the patient is symptomatic.</p>",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Competitive antagonist of the aldosterone receptor</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Increases sensitivity of the calcium-sensing receptor</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibits NaCI reabsorption in the early distal convoluted tubule</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">The Na<sup>+</sup>/K<sup>+</sup>/CIT cotransporter in the thick ascending limb of the loop of Henle</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 43-year-old woman with ESRD comes in because of pain in her extremities. Serum calcium is 7.8 mg/dL, and parathyroid hormone levels (iPTH) are 370 pg/mL (normal by this assay = 10-60 pg/mL). Calcium-containing phosphate binders and vitamin D are administered until the patient's serum calcium reaches 8.4 mg/dL. At this point, the physician prescribes a drug to treat the patient's osteolysis. Which of the following best describes the mechanism of action of this drug?</span></p>",
      "unique_key": "DT1166399",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166399,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Cinacalcet</strong> is a calcimimetic agent that acts by increasing the sensitivity of the calcium-sensing receptor (CaSR) on the parathyroid gland's chief cells to extracellular calcium. This enhanced sensitivity leads to suppression of parathyroid hormone (PTH) secretion.</p>\r\n<ul>\r\n<li><strong>In ESRD</strong>, reduced phosphate excretion leads to hyperphosphatemia &rarr; phosphate binds calcium &rarr;</li>\r\n<li>Hypocalcemia stimulates <strong>parathyroid gland hyperplasia</strong> &rarr; <strong>secondary hyperparathyroidism.</strong></li>\r\n<li>Elevated PTH causes <strong>bone resorption</strong> and <strong>osteolysis</strong>, worsening bone disease</li>\r\n<li><strong>Cinacalcet</strong> is used once serum calcium &ge;8.4 mg/dL, to suppress PTH secretion by mimicking calcium's action on CaSR</li>\r\n<li>Target iPTH level in dialysis patients is <strong>150-300 pg/mL</strong></li>\r\n<li>Other therapies: dietary phosphate restriction, phosphate binders, vitamin D and analogues</li>\r\n<li><strong>Surgery</strong> is indicated when iPTH &gt;800 pg/mL or when pharmacotherapy fails</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Competitive antagonist of the aldosterone receptor (Option A):</strong> Refers to spironolactone or eplerenone; used in hyperaldosteronism or heart failure, not effective in managing hyperparathyroidism.</p>\r\n<p><strong>Inhibits NaCl reabsorption in the early distal convoluted tubule (Option C):</strong> Refers to thiazide diuretics, which increase calcium reabsorption, not used for PTH suppression.</p>\r\n<p><strong>Inhibits the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle (Option D):</strong> Mechanism of loop diuretics like furosemide; leads to calcium loss, may worsen hypocalcemia in ESRD patients.</p>",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Bumetanide</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Cholecalciferol</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Levothyroxine</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Metolazone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old man with goitre undergoes a thyroidectomy. One week later, he develops carpopedal spasms, muscle and abdominal cramps, and tingling of his lips and hands. Laboratory studies show a serum calcium of 6.2 mg/dL and serum phosphate of 5.7 mg/dL. Which of the following drugs will most likely improve this patient's symptoms?</span></p>",
      "unique_key": "DT1166401",
      "question_audio": null,
      "question_video": null,
      "map_id": 1166401,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>This patient is presenting with signs and symptoms highly suggestive of <strong>hypoparathyroidism</strong>, a condition that occurs most frequently after thyroidectomy or the removal of a parathyroid adenoma. Hypoparathyroidism is a condition of parathyroid hormone (PTH) deficiency leading to decreased calcium levels and other electrolyte abnormalities.</p>\r\n<ul>\r\n<li>Normally, a fall in extracellular fluid ionised calcium concentration leads to stimulation of PTH secretion. When released, PTH enhances active reabsorption of calcium and magnesium from distal tubules and the thick ascending limb in the kidney, enhances the release of calcium from bones and enhances the absorption of calcium in the intestine by increasing the production of activated vitamin D. However, in hypoparathyroidism, PTH levels are greatly reduced, resulting in severe hypocalcemia.</li>\r\n<li>There are three principal reasons for low Ca2<sup>+</sup>in such cases\r\n<ul>\r\n<li>Low PTH reduces renal reabsorption of Ca<sup>++</sup>but increases reabsorption of phosphate.</li>\r\n<li>The resulting high plasma phosphate binds plasma Ca++, so plasma Ca<sup>++</sup></li>\r\n<li>Low PTH causes low production of the active form of vitamin D, so Ca<sup>++</sup>absorption in the small intestine is decreased.</li>\r\n</ul>\r\n</li>\r\n<li>Hypoparathyroidism is characterised by severe hypocalcemia and hyperphosphatemia, resulting in tetany, carpopedal spasms, muscle and abdominal cramps, and tingling of the lips and hands. A positive Chvostek sign (tapping the face in front of the ear elicits tetany) and Trousseau sign (abnormal muscular contractions elicited by applying a blood pressure cuff) will often be noted.\r\n<ul>\r\n<li>Since the blood calcium levels are often very low, either calcium gluconate or vitamin D preparations should be administered to correct the condition. Vitamin D preparations, such as Cholecalciferol, elevate calcium levels and also increase phosphate levels. Another treatment option would be to use the vitamin D3 analogue calcitriol. Calcitrol has a mechanism of action similar to that of cholecalciferol. Ergocalciferol is also used, but has a shorter duration and lower potency than cholecalciferol. Although further elevation of serum phosphate would be undesirable, vitamin D analogues are front-line therapy for hypoparathyroidism; phosphate levels may be addressed with phosphate binders or other measures.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Bumetanide (Option A):</strong> Loop diuretic; promotes calcium excretion, worsening hypocalcemia.</p>\r\n<p><strong>Levothyroxine (Option C):</strong> Replaces thyroid hormone; doesn't address calcium/phosphate imbalance from hypoparathyroidism.</p>\r\n<p><strong>Metolazone (Option D):</strong> Thiazide-like diuretic; mildly retains calcium but not adequate to treat severe hypocalcemia.</p>",
      "correct_choice_id": 122,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}